Verona Pharma Is Maintained at Buy by Truist Securities
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $38
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Verona Pharma (VRNA) and Hims & Hers Health (HIMS)
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Piper Sandler Remains a Buy on Verona Pharma (VRNA)
Wells Fargo Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $50
Wells Fargo Initiates Verona Pharma at Overweight With $50 Price Target
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Verona Pharma Analyst Ratings
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Buy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD Treatment
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Verona Pharma Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Verona Pharma (VRNA) Receives a Buy From Truist Financial
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Buy Rating for Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $37